Department of Biotechnology and Molecular Medicine, AI Virtanen Institute for Molecular Sciences, University of Kuopio, PO Box 1627, FIN-70211 Kuopio, Finland.
Cardiovasc Res. 2010 Apr 1;86(1):122-30. doi: 10.1093/cvr/cvp382. Epub 2009 Dec 2.
Vascular endothelial growth factors (VEGFs) and their receptors (VEGF-Rs) are among the most powerful factors regulating vascular growth. However, it has remained unknown whether stimulation of VEGF-R1, VEGF-R2 or both of the receptors produces the best angiogenic responses in myocardium. The aim of this study was to compare the VEGF-R1-specific ligand VEGF-B(186), VEGF-R2-specific ligand VEGF-E and VEGF-A(165,) which stimulates both receptors, regarding their effects on angiogenesis and left ventricular function in mice.
High-resolution echocardiography was used to guide the closed-chest injections of adenoviral (Ad) vectors expressing VEGF-B(186,) VEGF-E, and VEGF-A(165) into the anterior wall of the left ventricle in C57Bl/6J mice. Angiogenic and functional effects were analysed using histology, ultrasound and perfusion analyses 6 (D6) and 14 (D14) days after the Ad injection. AdVEGF-A(165) induced a strong angiogenic response seen as an enlargement of myocardial capillaries whereas angiogenesis induced by AdVEGF-B(186) and AdVEGF-E seemed more physiological. The increase in the capillary area was accompanied with an increase in myocardial perfusion at D6 after the gene injection. AdVEGF-A(165) and AdVEGF-E induced endothelial-specific proliferation whereas AdVEGF-B(186) mostly induced proliferation of cardiomyocytes. AdVEGF-A(165) induced more pronounced tissue damage than AdVEGF-B(186) and AdVEGF-E. Left ventricular function measured as ejection fraction did not change during the follow-up. AdVEGF-A(165) increased both VEGF-R1 and VEGF-R2 protein expression whereas AdVEGF-B(186) and AdVEGF-E did not affect endogenous receptor expression levels.
AdVEGF-B(186) and AdVEGF-E are equally potent in inducing therapeutic angiogenesis in mouse myocardium and produce less side effects than AdVEGF-A(165).
血管内皮生长因子(VEGFs)及其受体(VEGF-Rs)是调节血管生长的最强大因素之一。然而,刺激 VEGFR1、VEGFR2 或两种受体是否能产生最佳的心肌血管生成反应仍不清楚。本研究旨在比较 VEGF-R1 特异性配体 VEGF-B(186)、VEGF-R2 特异性配体 VEGF-E 和同时刺激两种受体的 VEGF-A(165),观察它们对小鼠血管生成和左心室功能的影响。
使用高分辨率超声心动图引导腺病毒(Ad)载体在 C57Bl/6J 小鼠左心室前壁进行封闭胸部注射,表达 VEGF-B(186)、VEGF-E 和 VEGF-A(165)。在 Ad 注射后 6(D6)和 14(D14)天,通过组织学、超声和灌注分析来分析血管生成和功能效应。AdVEGF-A(165)诱导了强烈的血管生成反应,表现为心肌毛细血管扩张,而 AdVEGF-B(186)和 AdVEGF-E 诱导的血管生成似乎更具生理性。基因注射后 6 天,毛细血管面积增加伴随着心肌灌注增加。AdVEGF-A(165)和 AdVEGF-E 诱导内皮特异性增殖,而 AdVEGF-B(186)主要诱导心肌细胞增殖。AdVEGF-A(165)引起的组织损伤比 AdVEGF-B(186)和 AdVEGF-E 更明显。左心室功能(射血分数)在随访期间没有变化。AdVEGF-A(165)增加了 VEGF-R1 和 VEGF-R2 蛋白表达,而 AdVEGF-B(186)和 AdVEGF-E 不影响内源性受体表达水平。
AdVEGF-B(186)和 AdVEGF-E 在诱导小鼠心肌治疗性血管生成方面同样有效,并且比 AdVEGF-A(165)产生的副作用更少。